Viridian Therapeutics Shares Plunge After Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 15 2026
0mins
Source: seekingalpha
Viridian Therapeutics Inc. shares fell 32% after hitting a 20-day low, following the announcement of phase 3 trial results for elegrobart, which met its primary endpoint for treating thyroid eye disease.
Despite the positive trial results, investor expectations were not met, leading to a significant stock decline. The efficacy data showed a responder rate of 54% in the four-week dosing group, but overall market sentiment was dampened by an analyst's disappointment regarding the drug's efficacy profile. Viridian plans to submit a Biologics License Application for elegrobart in Q1 2027, but the market reaction indicates skepticism about its future performance.
The implications of this decline suggest that while the trial results were technically positive, the market's reaction reflects a deeper concern about the drug's potential in a competitive landscape. Investors may need to reassess their expectations as the company moves forward with its plans.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRDN
Wall Street analysts forecast VRDN stock price to rise
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.990
Low
14.20
Averages
41.71
High
61.00
Current: 18.990
Low
14.20
Averages
41.71
High
61.00
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viridian's Lumvoa Therapy for Thyroid Eye Disease Set to Launch
- Lumvoa Therapy Progress: Viridian Therapeutics' Lumvoa therapy for thyroid eye disease (TED) is set to launch, marking a significant milestone for the company in treating this condition and potentially offering new options for patients.
- Market Potential: With TED affecting a large patient population, the introduction of Lumvoa is expected to address unmet medical needs, thereby presenting Viridian with substantial market opportunities and revenue potential.
- R&D Investment: Viridian has invested heavily in the development of Lumvoa, demonstrating the company's commitment to innovative treatment solutions, which aims to enhance its competitiveness in the biopharmaceutical industry.
- Future Outlook: The upcoming launch of Lumvoa may attract increased investor interest in Viridian, further driving up its stock price and bolstering market confidence.
See More
U.S. Stocks Close Higher, Led by Technology Gains
- Tech Stock Surge: On Monday, the S&P 500 rose by 1.18%, the Dow Jones increased by 0.59%, and the Nasdaq 100 jumped by 2.25%, indicating a strong rebound in technology stocks that boosted overall market performance and reflected growing investor confidence in the tech sector.
- Geopolitical Easing: The U.S. and Iran agreed to halt hostilities in the Strait of Hormuz ahead of peace talks, providing market support and alleviating investor concerns over geopolitical risks, which contributed to the stock market's upward movement.
- Oil Price Volatility: Although WTI crude oil prices surged over 2% due to escalating tensions, they retreated after the U.S. and Iran reached a temporary ceasefire, highlighting the market's sensitivity to oil price fluctuations and expectations for future economic growth.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator rose to 95.0, surpassing expectations of 94.3, suggesting signs of economic recovery that may further enhance investor optimism and promote capital inflows into the market.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Nasdaq 100 up 1.08%, primarily driven by gains in the Magnificent Seven tech stocks, indicating strong market confidence in the technology sector that may attract further investor interest.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, easing tensions in the Strait of Hormuz, which positively impacted the market as crude oil prices rose over 1%, while reducing demand for safe-haven assets, thus boosting stock prices.
- Economic Confidence Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, signaling signs of economic recovery that could influence future monetary policy decisions and further support market sentiment.
- Mixed Stock Performance: Stocks like Amazon and Tesla rose over 4%, while Apple saw a decline of 0.56%, reflecting varied market reactions to different companies, prompting investors to pay attention to individual stock fundamentals.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Dow Jones Industrial Average up 0.64% and the Nasdaq 100 up 0.67%, reflecting a strong rebound in technology stocks, particularly the Magnificent Seven, which significantly boosted overall market performance.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, agreeing to halt attacks in the Strait of Hormuz, paving the way for upcoming peace talks in Doha, which has lifted market sentiment and reduced investor demand for safe-haven assets.
- Oil Price Fluctuations: Although WTI crude oil prices rose over 1% due to escalating geopolitical tensions, the market's expectations for oil prices have moderated following the ceasefire agreement, indicating a focus on future supply-demand balance.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, reflecting optimistic market sentiment regarding economic recovery, which may further bolster investor confidence in the stock market.
See More
Universe Pharmaceuticals Acquires Best Praise International
- Acquisition Agreement: Universe Pharmaceuticals has entered into a definitive agreement to acquire Best Praise International for approximately $10.75 million, which is expected to enhance its R&D capabilities in areas such as age-related diseases and neurodegenerative disorders, thereby facilitating expansion in the Chinese pharmaceutical market.
- Patent Value Addition: The acquisition will add five China-based pharmaceutical patents to Universe Pharmaceuticals' portfolio, potentially creating opportunities for future licensing and co-development initiatives, further solidifying its product line targeting China's aging population.
- Clinical Advancements: NeOnc Technologies has received a second Investigational New Drug authorization from the Department of Health – Abu Dhabi for NEO100 in recurrent high-grade gliomas, with topline Phase 2a data expected by the end of July, enhancing the company's regulatory presence internationally.
- FDA Approval: Viridian Therapeutics' Lumvoa™ has been approved by the FDA as the first commercial product for thyroid eye disease, marking a significant milestone in the biopharmaceutical sector, with plans to submit a Biologics License Application for its subcutaneous candidate in Q1 2027 to further expand its product offerings.
See More
FDA Approves Viridian's Lumvoa for Thyroid Eye Disease
- Product Approval: The FDA has officially approved Viridian Therapeutics' Lumvoa for the treatment of thyroid eye disease, marking a significant breakthrough for the company in the ophthalmic sector and is expected to substantially increase its market share.
- Commercial Launch: The immediate commercial launch of Lumvoa will provide comprehensive support for patients, ensuring they can quickly access treatment, thereby enhancing Viridian's position in the highly competitive biopharmaceutical market.
- Market Potential: With a large patient population suffering from thyroid eye disease, the introduction of Lumvoa is anticipated to meet the urgent demand for effective treatment options, driving revenue growth and increasing brand recognition for Viridian.
- Strategic Implications: This approval not only opens up a new revenue stream for Viridian but may also attract investor interest, strengthening the company's capabilities for future research and market expansion.
See More
Viridian's Lumvoa Therapy for Thyroid Eye Disease Set to Launch
- Lumvoa Therapy Progress: Viridian Therapeutics' Lumvoa therapy for thyroid eye disease (TED) is set to launch, marking a significant milestone for the company in treating this condition and potentially offering new options for patients.
- Market Potential: With TED affecting a large patient population, the introduction of Lumvoa is expected to address unmet medical needs, thereby presenting Viridian with substantial market opportunities and revenue potential.
- R&D Investment: Viridian has invested heavily in the development of Lumvoa, demonstrating the company's commitment to innovative treatment solutions, which aims to enhance its competitiveness in the biopharmaceutical industry.
- Future Outlook: The upcoming launch of Lumvoa may attract increased investor interest in Viridian, further driving up its stock price and bolstering market confidence.
See More
U.S. Stocks Close Higher, Led by Technology Gains
- Tech Stock Surge: On Monday, the S&P 500 rose by 1.18%, the Dow Jones increased by 0.59%, and the Nasdaq 100 jumped by 2.25%, indicating a strong rebound in technology stocks that boosted overall market performance and reflected growing investor confidence in the tech sector.
- Geopolitical Easing: The U.S. and Iran agreed to halt hostilities in the Strait of Hormuz ahead of peace talks, providing market support and alleviating investor concerns over geopolitical risks, which contributed to the stock market's upward movement.
- Oil Price Volatility: Although WTI crude oil prices surged over 2% due to escalating tensions, they retreated after the U.S. and Iran reached a temporary ceasefire, highlighting the market's sensitivity to oil price fluctuations and expectations for future economic growth.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator rose to 95.0, surpassing expectations of 94.3, suggesting signs of economic recovery that may further enhance investor optimism and promote capital inflows into the market.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Nasdaq 100 up 1.08%, primarily driven by gains in the Magnificent Seven tech stocks, indicating strong market confidence in the technology sector that may attract further investor interest.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, easing tensions in the Strait of Hormuz, which positively impacted the market as crude oil prices rose over 1%, while reducing demand for safe-haven assets, thus boosting stock prices.
- Economic Confidence Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, signaling signs of economic recovery that could influence future monetary policy decisions and further support market sentiment.
- Mixed Stock Performance: Stocks like Amazon and Tesla rose over 4%, while Apple saw a decline of 0.56%, reflecting varied market reactions to different companies, prompting investors to pay attention to individual stock fundamentals.
See More
US Stocks Rise, Led by Technology Sector Gains
- Tech Sector Surge: Major US stock indices rose today, with the Dow Jones Industrial Average up 0.64% and the Nasdaq 100 up 0.67%, reflecting a strong rebound in technology stocks, particularly the Magnificent Seven, which significantly boosted overall market performance.
- Geopolitical Easing: The US and Iran reached a temporary ceasefire agreement, agreeing to halt attacks in the Strait of Hormuz, paving the way for upcoming peace talks in Doha, which has lifted market sentiment and reduced investor demand for safe-haven assets.
- Oil Price Fluctuations: Although WTI crude oil prices rose over 1% due to escalating geopolitical tensions, the market's expectations for oil prices have moderated following the ceasefire agreement, indicating a focus on future supply-demand balance.
- Economic Confidence Indicator Rise: The Eurozone's June economic confidence indicator increased to 95.0, surpassing expectations of 94.3, reflecting optimistic market sentiment regarding economic recovery, which may further bolster investor confidence in the stock market.
See More
Universe Pharmaceuticals Acquires Best Praise International
- Acquisition Agreement: Universe Pharmaceuticals has entered into a definitive agreement to acquire Best Praise International for approximately $10.75 million, which is expected to enhance its R&D capabilities in areas such as age-related diseases and neurodegenerative disorders, thereby facilitating expansion in the Chinese pharmaceutical market.
- Patent Value Addition: The acquisition will add five China-based pharmaceutical patents to Universe Pharmaceuticals' portfolio, potentially creating opportunities for future licensing and co-development initiatives, further solidifying its product line targeting China's aging population.
- Clinical Advancements: NeOnc Technologies has received a second Investigational New Drug authorization from the Department of Health – Abu Dhabi for NEO100 in recurrent high-grade gliomas, with topline Phase 2a data expected by the end of July, enhancing the company's regulatory presence internationally.
- FDA Approval: Viridian Therapeutics' Lumvoa™ has been approved by the FDA as the first commercial product for thyroid eye disease, marking a significant milestone in the biopharmaceutical sector, with plans to submit a Biologics License Application for its subcutaneous candidate in Q1 2027 to further expand its product offerings.
See More
FDA Approves Viridian's Lumvoa for Thyroid Eye Disease
- Product Approval: The FDA has officially approved Viridian Therapeutics' Lumvoa for the treatment of thyroid eye disease, marking a significant breakthrough for the company in the ophthalmic sector and is expected to substantially increase its market share.
- Commercial Launch: The immediate commercial launch of Lumvoa will provide comprehensive support for patients, ensuring they can quickly access treatment, thereby enhancing Viridian's position in the highly competitive biopharmaceutical market.
- Market Potential: With a large patient population suffering from thyroid eye disease, the introduction of Lumvoa is anticipated to meet the urgent demand for effective treatment options, driving revenue growth and increasing brand recognition for Viridian.
- Strategic Implications: This approval not only opens up a new revenue stream for Viridian but may also attract investor interest, strengthening the company's capabilities for future research and market expansion.
See More
